Exposure to hepatitis C virus (HCV) usually results in
persistent infection that often develops into chronic
liver disease.
Interferon-alpha (IFN) treatment comprises the foundation of current approved
therapy for chronic HCV
infection but is limited in overall efficacy. IFN is a major effector of innate
antiviral immunity and is naturally produced in response to
viral infection when viral
pathogen-associated molecular patterns (
PAMPs) are recognized as nonself and are bound by cellular pathogen recognition receptors (
PRRs), including
Toll-like receptors (TLRs) and the RIG-I-like receptors (RLRs). Within hepatocytes, RIG-I is a major PRR of HCV
infection wherein
PAMP interactions serve to trigger intracellular signaling cascades in the infected hepatocyte to drive IFN production and the expression of
interferon-stimulated genes (ISGs). ISGs function to limit virus replication, modulate the immune system, and to suppress virus spread. However, studies of HCV-host interactions have revealed several mechanisms of innate immune regulation and evasion that feature virus control of PRR signaling and regulation of hepatic innate immune programs that may provide a molecular basis for viral persistence.